product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
FoxP3
catalog :
98377
clonality :
monoclonal
host :
domestic rabbit
conjugate :
nonconjugated
clone name :
D2W8E
reactivity :
human
application :
immunocytochemistry, immunohistochemistry - paraffin section
more info or order :
Cell Signaling Technology product webpage
citations: 7
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4a
Wu Q, Tian A, Li B, Leduc M, Forveille S, Hamley P, et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J Immunother Cancer. 2021;9: pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 6a
Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier Pfistershammer K, et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019;10:4186 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1c
Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer. 2019;7:233 pubmed publisher
  • immunocytochemistry; human; 1:100; fig s6c
Carvajal Hausdorf D, Mani N, Velcheti V, Schalper K, Rimm D. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. J Immunother Cancer. 2017;5:81 pubmed publisher
Kovaleva O, Rashidova M, Samoilova D, Podlesnaya P, Mochalnikova V, Gratchev A. Immunosuppressive Phenotype of Esophagus Tumors Stroma. Anal Cell Pathol (Amst). 2020;2020:5424780 pubmed publisher
Jiang F, Yu W, Zeng F, Cheng G, Xu J, Yang S, et al. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma. BMC Cancer. 2019;19:503 pubmed publisher
Mattox A, Lee J, Westra W, Pierce R, Ghossein R, Faquin W, et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. Cancer Res. 2017;77:6365-6374 pubmed publisher
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.